Pharmaco-ecomonic study of oral anti-hypertensive drugs available in Indian pharmaceutical market

Sandeep Singh Bhadoriya; Prashant Wadagbalkar

doi:10.18203/2319-2003.ijbcp20231894

Authors

Sandeep Singh Bhadoriya Department of Pharmacology, Index Medical Hospital and Research Centre, Malwanchal University, Indore, Madhya Pradesh, India
Prashant Wadagbalkar Department of Pharmacology, Amaltas Medical College, Hospital and Research Centre, Dewas, Madhya Pradesh, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20231894

Keywords:

Hypertension, Pharmacoeconomics, Diabetes mellitus

Abstract

Background: Hypertension is a global public health problem. To decrease its morbidity and mortality it needs life-long treatment. There is a wide range of variation in the prices of antihypertensive drugs marketed in India. Thus, a study was planned to evaluate the difference in cost of different brands of same active drug by calculating percentage variation of cost.

Methods: The cost of different brands of commonly used anti-hypertensive drugs was sorted out by referring latest CIMS, MIMS and drug today. The cost of 10 dosage forms (tablets/capsules) in INR of each brand, cost ratio and percentage cost variation were calculated and evaluated.

Results: The cost of different anti-hypertensive drugs were analysed and minimum and maximum cost of the drugs in a particular dosage are tabulated. The cost variation is analysed with SPSS software 2.0 version with tools of median and interquartile range. The variation in cost of most of the anti-hypertensive drugs is more than 100%. It’s found maximum in amlodipine (5 mg) with cost variation of 625%, atenolol 100 mg with cost variation of 413%.

Conclusions: The average percentage cost variation of the same molecules of antihypertensive drugs manufactured by different pharmaceuticals company in India is very wide. So, government, pharmaceutical company, marketing manager and prescribing doctors should think about variation of cost and do needful for providing maximum beneﬁts to the patients receiving antihypertensive drugs.

Metrics

Metrics Loading ...

References

Park K. Park’s textbook of preventive and social medicine. 23rd ed. India: Bhanot Publishers; 2015.

Kokiwar PR, Gupta SS, Durge PM. Prevalence of hypertension in a rural community of central India. J Assoc Physicians India. 2012;60:26-9.

Patel V, Chatterji S, Chisholm D, Ebrahim S, Gopalakrishna G, Mathers C, et al. Chronic diseases and injuries in India. Lancet. 2011;377(9763):413-28.

Indrayan A. Epidemiology of hypertension. J Assoc Physicians India. 1994;42(2):175-6.

Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2224-60.

Gupta R. Trends in hypertension epidemiology in India. J Hum Hypertens. 2004;18(2):73-8.

Mackay J, Mensah GA, Greenlund K. Atlas of heart disease and stroke. Geneva: WHO; 2004.

Mohan S, Campbell N, Chockalingam A. Time to effectively address hypertension in India. Indian J Med Res. 2013;137(4):627-31.

Johannesson M, Le Lorier J. How to assess the economics of hypertension control programmes. J Hum Hypertens. 1996;10:S93-4.

Hilleman DE, Mohiuddin SM, Lucas BD, Stading JA, Stoysich AM, Ryschon K. Cost-minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension. Clin Ther. 1994;16(1):88-102.

Patel D, Thiyangu R, Surulivelrajan M, Patel H, Pandey S. Price variability among the oral antibiotics available in a South Indian Tertiary Care Hospital. J Clin Diagn Res. 2009;3(6):1871-5.

Shankar PR, Subish P, Mishra P, Lalit M. Ambiguous pricing of Nepalese medicines. J Inst Med. 2006;28(3):35-43.

Mandal M, Mandal SC, Das SC. A critical study on availability and price variation between different brands: Impact on access to medicines. Indian J Pharm Sci. 2007;69(1):160-3.

Thomas M. Rational drug use and essential drug concept. In: Parthasarthi G, Nyfort Hasen K, eds. A Textbook of Clinical Pharmacy Practice. 1st ed. Hyderabad: Orient Longman: 72-73.

Laxminarayana K, Satish GR. Cost variation analysis of antihypertensive drugs available in Indian market: An Economic Prospective. Int J Pharm Sci Res. 2016;7(5):2050-6.

Karve A, Chattar K. Cost analysis study of oral antihypertensive agents available in Indian market. Int J Basic Clin Pharmacol. 2014;3(3):479-83.

Limaye D. Cost-effectiveness study of Antihypertensive drugs in Mumbai, India. Int J Life Sci Pharma Res. 2018;8(1):97-103.

WHO. Drug ﬁnance, 2023. Available at: http://www.whoindia.org/EN/Section2/Section/Section160-959.htm. Accessed on 06 May 2023.

Sarkar PK. A rational drug policy. Indian J Med Ethics. 2004;12(1):30-5.

Roy V, Rewari S. Ambiguous drug pricing: A physicians dilemma. IJP. 1998;30(6):404-11.

Wertheimer AI, Grumer SK. Overview of International Pharmacy Pricing. Pharmacoecon. 1992;2(6):449-55.

Berki SE, Richard JW, Weeks HA. The Mysteries of Prescription Pricing in Retail Pharmacies. Med Care. 1977;15(3):241-50.

Dang A, Rataboli PV. Antimicrobial price variation: Conundrum of medical profession! J Postgrad Med. 2007;53(1):72-4.

Dawadi S, Rao BS, Khan GM. Pattern of antimicrobial prescription and its cost analysis in respiratory tract infection. Kathmandu University. J Sci Eng Technol. 2005;1(1):1-9.

Kumar V, Gupta NV, Kumar KA. A Comparison between old and latest system in DPCO. Int J Pharm Pharma Sci. 2014;6(2):19-20.

NPPA. Compendium of notiﬁed celling prices of schedule drugs, 2015. Available at: http://www.nppaindia.nic/cellingprice. Accessed on 06 May 2023.